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Human Plasma Phospholipid Transfer Protein Increases the
Antiatherogenic Potential of High Density Lipoproteins in
Transgenic Mice
Rien van Haperen,* Arie van Tol,* Pieter Vermeulen, Matti Jauhiainen, Teus van Gent,
Paul van den Berg, Sonja Ehnholm, Frank Grosveld, Arthur van der Kamp, Rini de Crom
Abstract—Plasma phospholipid transfer protein (PLTP) transfers phospholipids between lipoprotein particles and alters
high density lipoprotein (HDL) subfraction patterns in vitro, but its physiological function is poorly understood.
Transgenic mice that overexpress human PLTP were generated. Compared with wild-type mice, these mice show a 2.5-
to 4.5-fold increase in PLTP activity in plasma. This results in a 30% to 40% decrease of plasma levels of HDL
cholesterol. Incubation of plasma from transgenic animals at 37°C reveals a 2- to 3-fold increase in the formation of
pre-b-HDL compared with plasma from wild-type mice. Although pre-b-HDL is normally a minor subfraction of HDL,
it is known to be a very efficient acceptor of peripheral cell cholesterol and a key mediator in reverse cholesterol
transport. Further experiments show that plasma from transgenic animals is much more efficient in preventing the
accumulation of intracellular cholesterol in macrophages than plasma from wild-type mice, despite lower total HDL
concentrations. It is concluded that PLTP can act as an antiatherogenic factor preventing cellular cholesterol overload
by generation of pre-b-HDL. (Arterioscler Thromb Vasc Biol. 2000;20:1082-1088.)
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Plasma phospholipid transfer protein (PLTP) is able topromote the net transfer of phospholipids between
plasma lipoproteins1–4 and mediate the conversion of HDL.5,6
Because plasma levels of HDL are among the best indicators
for the risk of atherosclerosis in epidemiological studies,7,8
PLTP could play a role in the prevention of the development
of coronary heart disease and stroke via its effect on HDL.
HDLs are antiatherogenic because they mediate efflux of
cholesterol from peripheral cells and transport cholesterol to
the liver, for excretion and degradation to bile acids. This
process is known as reverse cholesterol transport.8–10 It has
been postulated that the antiatherogenic effect of HDL can be
attributed mainly to a quantitatively minor subclass of HDL,
called pre-b-HDL.11,12 This assumption is based on in vitro
studies showing that pre-b-HDL is a very efficient acceptor
of cellular cholesterol.13,14 The origin of pre-b-HDL is not
well understood, but the available evidence suggests that
PLTP participates in its generation, at least in vitro.15
After the cloning of a human PLTP (HuPLTP) cDNA,16 2
groups independently generated transgenic mice for Hu-
PLTP.17,18 Unfortunately, these mice showed low levels of
expression of the transgene, and as a result, only small effects
on plasma lipoproteins were observed. Changes in HDL
levels and subfractions could be demonstrated only in a
compound transgenic background with human apoA-I.18 Re-
cently, the generation of a PLTP knockout mouse was
reported by Jiang et al.19 These mice show a decrease of
plasma cholesterol in all lipoprotein classes.
In the present study, we report the generation of transgenic
mice that overexpress HuPLTP 2.5- to 4.5-fold. This results
in decreased plasma total HDL cholesterol levels, in in-
creased formation of pre-b-HDL, and in a high plasma
capability to prevent cholesterol accumulation in
macrophages.
Methods
Generation of HuPLTP Transgenic Mice
A human cosmid library was constructed from high-molecular-
weight DNA isolated from the blood of a healthy volunteer. This
library was screened for cosmids containing the PLTP gene by using
HuPLTP cDNA (kindly donated by Drs A-Y. Tu and J.J. Albers,
Northwest Lipid Research Laboratories, University of Washington,
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Seattle) as a probe. Isolated cosmids were mapped by using restric-
tion fragments from the cDNA, and a cosmid containing the
complete PLTP gene20 was selected. Vector sequences were re-
moved by restriction endonuclease digestion, and DNA was dis-
solved in microinjection buffer (10 mmol/L Tris-HCl, pH 7.5, and
0.1 mmol/L EDTA) at a concentration of 1 to 2 mg/mL. The DNA
was microinjected into fertilized oocytes from FVB mice. These
oocytes were transferred into the oviducts of pseudopregnant foster
females. All animal experiments were performed in compliance with
the Guidelines of the Ethical Committee on the Use of Laboratory
Animals of the Erasmus University Rotterdam (No. 132.97.06) and
with the European Committee Standards on the care and use of
laboratory animals (Ministry of Welfare, Health, and Cultural
Affairs, the Netherlands).
DNA Analysis
Genomic DNA was isolated from tail clips of 10-day-old mice and analyzed
for the presence of the HuPLTP transgene by polymerase chain reaction
(PCR) analysis: sense primer 59-GCCACAGCAGGAGCTGATGC-39,
antisense primer 59-GCGGATGGACACACCCTCAGC-39; 25 to 30 cy-
cles (94°C for 1 minute, 65°C for 1 minute, and 72°C for 1 minute).
Breeding and Treatment of Transgenic Mice
Transgenic founder mice were bred with FVB mice to obtain
transgenic mice. FVB transgenic HuPLTP mice were backcrossed
with C57Bl/6 mice for 4 generations. These mice were intercrossed
to obtain wild-type, hemizygous, and homozygous HuPLTP trans-
genic mice. Animals were kept on regular chow and fasted overnight
before collection of blood from the orbital plexus.
Gene Expression Analysis by RT-PCR
Total RNA was isolated from various tissues obtained freshly
from either wild-type, hemizygous, or homozygous HuPLTP
transgenic mice. cDNA was obtained by reverse transcription
(RT) primed by oligo(dT). This was used in PCR reactions in the
presence of [32P]ATP (20 cycles at 94°C for 1 minute, 62°C for 1
minute, and 72°C for 1 minute). Primers used were as follows: for
HuPLTP, sense 59-CCTGCTGAGCCCAGCAGTG-39, antisense
59-CTGGACCTCAGGCTGGTCTG-39; for murine PLTP (Mu-
PLTP), sense 59-TTGACTCTGCCATGGAGAGC-39, antisense
59-GCTCCACTTCGGGCAACATG-39; and for hypoxanthine-
guanine phosphoribosyltransferase, sense 59-CGAAGTGTT-
GGATACAGGCC-39, antisense 59-GGCAACATCAACAGG-
ACTCC-39. PCR products were run on polyacrylamide gels and
visualized by using a PhosphorImager (Molecular Dynamics).
Assay of Plasma PLTP Activity
Plasma PLTP activity was assayed by using a phospholipid vesicle–
HDL system.1,21 EDTA-plasma samples (25 mL of plasma diluted
1:75) were incubated with [3H]dipalmitoylphosphatidylcholine-
labeled (Amersham) phosphatidylcholine vesicles and excess pooled
normal HDL for 45 minutes at 37°C. After incubation, the vesicles
were precipitated as described,21 and the radioactivity transferred to
HDL was counted in the supernatant. Standard curves based on
dilutions of human plasma were included in each run. The measured
activity is linear with time for 1 hour. All samples were analyzed in
duplicate, and blanks without plasma were subtracted. Duplicates of
pooled human plasma, stored at 270°C, were also measured in each
series (reference plasma). The between-assay coefficient of variation
of reference plasma was 4.1%. Activities are expressed as micro-
moles of phosphatidylcholine transferred per milliliter of plasma per
hour (mmol z mL21 z h21).
Anti-HuPLTP Polyclonal Antibodies
A synthetic peptide was made containing amino acids 470 to 493 of
HuPLTP (Chiron Mimotopes Peptide Systems). The peptide was
chosen to obtain an antibody that recognizes HuPLTP specifically,
without cross-reaction with the MuPLTP. Its sequence has a simi-
larity of 69% with the corresponding murine sequence (GenBank
accession numbers of the human and murine sequences are L26232
and U37226, respectively). The peptide was coupled to keyhole
limpet hemocyanin. New Zealand White rabbits were immunized
with the peptide-hemocyanin complex. Amounts of 0.15 mg of the
complex were given in a volume of 0.3 mL each time at intervals of
3 weeks. Blood samples were taken after each period of 3 weeks, and
the generation of antibodies was followed by Western blot analysis.
Starting after the second booster injection of the antigen complex,
serum from immunized rabbits (diluted 1:1000) displayed a strong
positive reaction with human plasma and with purified HuPLTP.
Furthermore, the reaction with antibody was monospecific, because
in both samples only 1 band with an identical molecular mass of 80
kDa was recognized. This molecular mass corresponds to the
HuPLTP band obtained with plasma from transgenic animals shown
in Figure 2. The antibody also shows a strong reaction with
recombinant HuPLTP, which was used as an internal standard in all
Western blotting experiments but does not recognize any protein in
wild-type mouse plasma (see Figure 2).
Anti-Mouse ApoA-I Polyclonal Antibodies
ApoA-I was purified from mouse plasma HDL (density range 1.063
to 1.21 g/mL) essentially as described22 and used to immunize
rabbits by subcutaneous injection with 100 mg of mouse apoA-I;
standard procedures were used.
Quantification of Plasma Lipids and ApoA-I
Total cholesterol was enzymatically determined with the F-Chol kit
(Boehringer-Mannheim) after hydrolysis of cholesteryl esters with
cholesterol esterase from Candida cylindracea (Boehringer-
Mannheim). Phospholipids were measured enzymatically with a
PAP150 kit (BioMe´rieux).
Mouse apoA-I was quantified by a sandwich ELISA, with use of
a polyclonal rabbit anti-mouse apoA-I IgG, performed in 96-well
plates coated with this antibody. Purified mouse apoA-I was used as
a primary standard. Plasma samples were diluted in PBS1Tween 20
(0.1%) with BSA (0.5%). Bound apoA-I was detected by the
addition of polyclonal rabbit anti-mouse apoA-I, conjugated to
horseradish peroxidase. The assay is linear in the range of 6.5 to 420
ng/mL.
Measurement of Plasma Lipoprotein Profiles by
Gel Filtration
Lipoprotein cholesterol profiles in mouse EDTA-plasma were ob-
tained by gel permeation chromatography on HR10/30 FPLC col-
umns in tandem that were filled with Superose 6 and Superose 12
(preparation grade, Pharmacia Biotechnology), respectively. Col-
umns were equilibrated and run in 0.9% NaCl containing 0.02%
NaN3, 5 mmol/L EDTA, and 2 mmol/L sodium phosphate buffer, pH
7.4. Pooled plasma samples obtained from 5 mice were filtered
through 0.45-mm filters (diameter 13 mm, Millipore), and 0.5 mL of
plasma was loaded onto the Superose 6 column. The separation was
performed at 4°C with a flow rate of 0.1 mL/min. Fractions of 0.8
mL were collected for measurement of cholesterol, phospholipids,
and PLTP activity.
Quantification of Pre-b-HDL by Crossed
Immunoelectrophoresis
Freshly isolated plasma samples from mice were either directly
frozen or incubated at 37°C in the presence of iodoacetate to measure
the formation of pre-b-HDL in vitro. Iodoacetate (1 mmol/L) was
added for complete inhibition of lecithin:cholesterol acyl transferase
(LCAT). This prevents maturation of the formed pre-b-HDL into
a-HDL by LCAT activity. The LCAT inhibitor had no effect on the
plasma pre-b-HDL concentration if added to freshly isolated plasma
(not shown).
The crossed immunoelectrophoresis consisted of agarose electro-
phoresis in the first dimension for separation of lipoproteins with
pre-b and a mobility. Electrophoresis in the second dimension (ie,
antigen migration from the first gel into an anti–apoA-I–containing
gel) was used to quantitatively precipitate apoA-I. Lipoprotein
electrophoresis was carried out in 1% (wt/vol) agarose gels in
barbital buffer (50 mmol/L, pH 8.6) and run in an LKB 2117 system
(4°C for 2 hours, 250 V). Plasma was applied at 5 mL per well. The
track of the first agarose gel was excised and annealed with melted
agarose to a gel containing 7.5% (vol/vol) rabbit anti-mouse apoA-I
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antiserum that was cast on GelBond film (Pharmacia). The plate was
run in an LKB 2117 system (4°C for 20 hours, 50 V) in barbital
buffer. Unreacted antibody was removed by extensive washing in
PBS. The gel was stained with Coomassie brilliant blue R250 and
subsequently dried. Areas under the pre-b-HDL and a-HDL peaks
were calculated by multiplication of peak height and width at half
height. The pre-b-HDL area is expressed as a percentage of the sum
of a-HDL and pre-b-HDL areas. Pre-b-HDL concentrations are also
given in absolute amounts (micrograms of apoA-I present in pre-b-
HDL per milliliter plasma). These values were calculated from the
percentage of apoA-I present in pre-b-HDL and the total plasma
apoA-I concentrations.
Cholesterol Flux Experiments With Mouse
Peritoneal Macrophages
The ability of mouse heparin-plasma to interfere with the intracel-
lular formation by acyl coenzyme A:cholesterol acyltransferase
(ACAT) of labeled cholesteryl oleate from [3H]oleate and acetylated
LDL (AcLDL)-derived cholesterol was tested by using the assay
developed by Brown et al.23 The formation of labeled cholesteryl
esters from [3H]oleate by ACAT is an estimate of intracellular
cholesterol concentration.
BSA (fraction V grade) was delipidated by extraction of free fatty
acids with activated carbon.24 [9,10(n)3H]Oleic acid (10.0 Ci/mmol,
Amersham) was complexed to BSA after evaporating 0.1 mmol of
oleic acid (48 Ci/mol) to dryness under a stream of nitrogen.
Subsequently, 10 mL of 12% (wt/vol) fatty acid–free BSA in DMEM
at 56°C was added to the dried oleate and sterilized by passage
through a 0.22-mm filter.
AcLDL was prepared from LDL (density range 1.019 to 1.063
g/mL), isolated from human plasma by differential centrifugation,
and subsequently acetylated by repeated additions of acetic anhy-
dride.25 Increased electrophoretic mobility of the AcLDL was
confirmed by agarose electrophoresis at pH 8.6.12
C57Bl/6 mice were elicited by intraperitoneal injection of 0.8 mL
of eliciting agent, prepared from Baker’s thioglycollate (DIFCO)
according to the manufacturer’s instructions. After 4 days, macro-
phages were obtained as described.26 The macrophage monolayers
were washed with DMEM and incubated with 500 mL aliquots of
DMEM that contained 3 mg/mL AcLDL, 0.1 mmol/L BSA-
[3H]oleate (48 Ci/mol), and plasma that was diluted (12 times) from
fasted mice. After 18 hours, medium was removed, and the cells
were washed twice with PBS. Cholesteryl esters were extracted from
the intact monolayers with 1 mL hexane-isopropanol (3:2 [vol/vol])
and purified by thin-layer chromatography as previously described.27
Labeled cholesteryl ester bands were excised from the silica, and
radioactivity was determined. Protein was extracted from the cell
remnants with 0.1 mol/L NaOH and quantified by the method of
Lowry et al28 using BSA as a standard. Duplicate assays were
performed for each plasma sample.
Statistics
Data are given as mean6SD. Differences between groups were
analyzed by 1-way ANOVA. The Bonferroni correction was used for
multiple pairwise comparisons when the ANOVA indicated a
significant effect.
Results
Generation of Transgenic Mice
A cosmid clone containing the complete HuPLTP gene was
isolated and analyzed by Southern blotting. Approximately
15 kb 59 to the first exon and ’3.5 kb 39 to the last exon of
the PLTP gene were present in the cosmid as well. The 39
end, but not the 59 end, of the lysosomal protective protein
gene was included (Figure 1). The purified 35-kb cosmid was
microinjected in fertilized oocytes. This resulted in 27 new-
born mice, 2 of which harbored the transgene, as determined
by PCR analysis and Southern blotting (data not shown).
Both founder mice were bred into 2 independent lines of
HuPLTP transgenic mice.
Expression of the Transgene
PLTP activity was measured in plasma samples of mice from
2 HuPLTP transgenic lines. In line 1, PLTP activity in the
plasma was increased by 281% compared with the activity in
the plasma from wild-type mice (Table 1), whereas in line 2,
activity was increased by 262% (not shown). Subsequent
analyses were performed with line 1 only. The use of either
human HDL or mouse HDL as acceptor in the PLTP activity
assay showed the same differences between wild-type, hemi-
zygous, and homozygous transgenic animals, demonstrating
that HuPLTP interacts with human HDL and mouse HDL
(not shown).
The expression of the transgene was confirmed by Western
blotting (Figure 2). An antibody that reacts specifically with
human PLTP was used. Compared with hemizygous trans-
genic mice, the mice homozygous for the transgene showed a
higher plasma protein level of HuPLTP. No immunoreactive
PLTP was detected in wild-type mice, because the antibody
used does not cross-react with MuPLTP. Human recombinant
PLTP was used as a positive control and gave 1 immunore-
active band at a relatively low molecular weight because of
the lower extent of glycosylation in the baculovirus expres-
sion system.
The transgene was found to be expressed in all tissues
analyzed (Figure 3), with relatively high mRNA levels in
adrenal, testis, and (to a lesser extent) lung. Moderate mRNA
levels were present in liver, kidney, intestine, brain, and
spleen. The mRNA expression of the endogenous PLTP gene
is highest in adrenal, testis, and lung. The prominent expres-
sion in lung tissue is found for MuPLTP but not for the
(human) transgene. The expression of endogenous PLTP was
Figure 1. Schematic drawing of PLTP and lysosomal protective
protein (LPP) genes, which are on opposite DNA strands.20 The
sequences included in the cosmid used to generate transgenic
mice are indicated.
TABLE 1. PLTP Activity, ApoA-I, and Lipid Concentrations in Plasma of HuPLTP
Transgenic Mice
PLTP Activity,
mmol z mL21 z h21
Cholesterol,
mmol/L
Phospholipids,
mmol/L
ApoA-I,
mg/mL
Wild-type (n511) 32.666.2 1.6560.25 2.1160.26 1.0960.33
Hemizygotes (n519) 91.169.3*† (280%) 1.2860.17‡§ (77%) 1.7860.22‡ (84%) 0.8660.23 (79%)
Homozygotes (n57) 142.5625.2* (437%) 1.0160.27* (62%) 1.5360.29* (72%) 0.7560.24‡ (69%)
Values are mean6SD. Values between brackets are percentage of the wild-type values. For further details see Methods.
*P,0.001 vs wild-type mice; †P,0.001 vs homozygous mice; ‡P,0.05 vs wild-type mice; and §P,0.05 vs homozygous mice.
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not affected by HuPLTP expression in any of the tissues
tested (Figure 3).
Effects of HuPLTP Overexpression on Plasma
Lipids and Lipoproteins
The overexpression of PLTP resulted in a decrease in plasma
cholesterol levels in the HuPLTP hemizygous transgenic
mice and a further decrease in levels in the homozygous
transgenic mice (Table 1). Plasma levels of cholesterol,
phospholipids, and apoA-I were decreased by about the same
extent, indicating that the decrease reflects a lowering of
HDL, which is the major lipoprotein in mouse plasma.
Separation of plasma lipoproteins by gel filtration confirmed
that the decrease in plasma lipids can be largely attributed to
a decreased level of HDL (fractions 15 to 18), because only
minor changes were found in VLDL (fraction 4 to 6) and
LDL (fraction 8 to 11), as seen in Figure 4. The peak of PLTP
activity was found in fractions 13 to 15 on filtration of plasma
from wild-type mice, as well as plasma from HuPLTP
transgenic mice (Figure 4).
To investigate changes in HDL subclass distribution,
mouse plasma was analyzed by crossed immunoelectro-
phoresis (Figure 5). Plasma samples from wild-type, hemi-
zygous, and homozygous HuPLTP transgenic mice were
collected and incubated in the presence of an inhibitor of
LCAT to prevent maturation of the formed pre-b-HDL into
a-HDL.14 The formation of pre-b-HDL particles is clearly
increased in plasma from transgenic mice compared with
wild-type mice. Table 2 gives the pre-b-HDL values,
before and after incubation in the presence of the LCAT
inhibitor. No significant differences were found in freshly
frozen plasma between the different genotypes. Before
incubation, the percentage of pre-b-HDL tends to be
highest in the homozygous HuPLTP transgenic animals,
but the differences between genotypes are not significant.
However, in incubated samples, clear differences arise
with the highest relative and absolute concentrations of
pre-b-HDL in the transgenic animals.
Figure 2. Western blot analysis of plasma levels of HuPLTP in
transgenic mice. Five microliters of mouse plasma (diluted 10
times) was loaded per lane. SDS-PAGE was carried out in
12.5% (wt/vol) gels under reducing conditions, and proteins
were electrophoretically transferred to polyvinylidine difluoride
membranes and visualized with a rabbit polyclonal antibody
raised against a synthetic peptide with identity to amino acids
470 to 493 of HuPLTP. Goat anti-rabbit IgG conjugated to per-
oxidase was used as a secondary antibody. Antigen-antibody
complexes were visualized by chemiluminescence with the ECL
system (Amersham). Blots were exposed for 20 seconds to a
Kodak XAR-5 film. The abbreviation rc refers to human recombi-
nant PLTP from a baculovirus expression system. Human
recombinant PLTP displays a relatively lower molecular mass
because of differences in glycosylation when produced in the
baculovirus expression system. Plasma from wild-type, hemizy-
gous, and homozygous HuPLTP mice is indicated by wt, he,
and ho, respectively.
Figure 3. Expression of PLTP in various tissues. Total RNA was
isolated from various tissues of wt, he, or ho HuPLTP transgenic
mice. RNA levels of either the transgene (HuPLTP) or the en-
dogenous murine gene (MuPLTP) were examined by gel electro-
phoresis of RT-PCR products. RT-PCR on hypoxanthine-
guanine phosphoribosyltransferase was used as a loading
control.
Figure 4. Gel filtration of plasma from wt mice and hemizygous
HuPLTP transgenic (HuPLTPtg) mice. Pooled plasma samples
(0.5 mL) were run on a Superose 6 and Superose 12 column in
tandem. For details see Methods.
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Effect of Wild-Type and Transgenic Plasma on
Accumulation of AcLDL-Derived Cholesterol in
Mouse Peritoneal Macrophages
We investigated whether differences in the HDL-subfraction
pattern affect the ability of wild-type and transgenic plasma
to interfere with the esterification of intracellular cholesterol
by ACAT. ACAT activity determined in this manner is a
measure of the intracellular cholesterol concentration. Mouse
peritoneal macrophages were incubated in the presence of
[3H]oleate, AcLDL, and diluted mouse plasma containing the
acceptor HDL particles (see Methods). Figure 6 shows that
the formation of labeled cholesteryl oleate by ACAT was
25.769.7% lower in the presence of hemizygous transgenic
plasma compared with wild-type plasma, indicating less
accumulation of cellular cholesterol in the presence of plasma
from transgenic animals. Thus, in spite of a lower HDL
cholesterol concentration, transgenic mouse plasma has the
ability to prevent cholesterol accumulation to a greater extent.
With plasma from homozygous HuPLTP transgenic mice, a
42.4613.2% decrease in ACAT activity (compared with
wild-type plasma; see Figure 6) is measured, showing even
less accumulation, indicative of a dose-response effect of
PLTP on the prevention of cholesterol accumulation.
Discussion
We generated transgenic mice for HuPLTP that have up to a
4.5-fold elevation of plasma PLTP activity levels. The total
plasma concentrations of cholesterol, phospholipids, and
apoA-I are decreased because of a 30% to 40% reduction in
total HDL. Gel filtration, which is used to measure the plasma
lipoprotein profile, confirmed the decrease in HDL choles-
terol and showed little variation in LDL and VLDL. No
change in HDL size was detected.
Plasma pre-b-HDL concentrations are unchanged in HuPLTP
transgenic mice (Table 2). This does not preclude the possibility
of increased turnover of pre-b-HDL in the transgenic animals.
Pre-b-HDL is the substrate of plasma LCAT that converts it into
mature a-HDL, normally carrying most of the circulating
plasma HDL cholesterol.14 The formation of pre-b-HDL during
plasma incubation at 37°C is therefore masked by the LCAT
reaction, and the maximal capacity for pre-b-HDL formation
can be measured only when LCAT is inactive. For this reason,
plasma was incubated in the presence of an LCAT inhibitor.
These experiments revealed that the relative and absolute plasma
levels of pre-b-HDL are clearly increased in plasma from
transgenic animals incubated under these conditions (Table 2).
These data indicate that rapid pre-b-HDL conversion to a-HDL,
driven by LCAT, may obscure the effects of the HuPLTP gene
on plasma pre-b-HDL levels in vivo. Our data imply that
HuPLTP transgenic plasma has a much greater ability to
Figure 5. ApoA-I immunoprecipitation patterns of plasma from
wild-type or HuPLTP transgenic mice obtained after crossed
immunoelectrophoresis. The figure shows a representative display
of the pre-b-HDL and a-HDL bands obtained by analysis of mouse
plasma, incubated for 3 hours at 37°C in the presence of iodoace-
tic acid (1 mmol/L), an inhibitor of LCAT. Samples were then ana-
lyzed by crossed immunoelectrophoresis as described in Methods.
To confirm monospecificity of the anti–apoA-I antibody toward
a-HDL and pre-b-HDL fractions, we performed immunoelectro-
phoresis as described.29 Two single precipitation arches appeared
without the formation of spurs, indicating that the antibody recog-
nizes immunologically identical determinants in both HDL subfrac-
tions.30 Left, Plasma from a wild-type mouse. Right, Plasma from a
homozygous HuPLTP transgenic mouse. The positions of pre-b-
HDL and a-HDL migration are indicated.
TABLE 2. Pre-b-HDL Levels in Plasma of HuPLTP Transgenic
Mice Before and After Incubation at 37°C
Relative Pre-b-HDL, %
Total Plasma ApoA-I
Absolute Pre-b-HDL,
mg/mL ApoA-I in Pre-b
Plasma Incubation Plasma Incubation
No Yes No Yes
Wild-type (n59) 3.761.8 7.862.9 45631 93657
Hemizygotes (n510) 3.062.0 21.063.0*† 28623 181658‡
Homozygotes (n510) 5.162.2 27.563.4* 39623 207662*
Values are mean6SD. For details see Methods.
*P,0.001 vs wild-type mice; †P,0.001 vs homozygous mice; and ‡P,0.01 vs
wild-type mice.
Figure 6. Esterification of cholesterol by ACAT in peritoneal
macrophages incubated simultaneously with AcLDL, [3H]oleate,
and plasma of wt, he, or ho HuPLTP transgenic mice. Plasma
was obtained from age-matched wt, he, and ho HuPLTP trans-
genic mice. Peritoneal macrophages were incubated for 18
hours in the presence of 3 mg/mL AcLDL, 0.1 mmol/L
[3H]oleate-BSA (48 Ci/mol), and diluted mouse plasma. Esterifi-
cation by ACAT is expressed as disintegrations per minute
(dpm) in cholesteryl oleate per microgram cell protein. A
decreased esterification indicates a decreased cellular choles-
terol concentration. For further details, see Methods. Values for
individual plasma samples are shown (open circles), as well as
mean values (closed circles) with standard deviations (vertical
bars). In the absence of plasma, ACAT activity was 1770690
dpm/mg. ACAT activity was very low in the absence of AcLDL:
16.060.4 dpm/mg with wt plasma. Values for he and ho mice
differed at the P50.021 (n58) and P50.001 (n56) level from
those for wt mice (n57), respectively. The data presented show
a typical example of 4 independent experiments performed.
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generate pre-b-HDL than does wild-type plasma, in spite of only
marginal differences in pre-b-HDL levels.
HuPLTP transgenic mice have been described previously by
2 other groups, but these models did not show an appreciable
overexpression of the transgene. The mice described by Albers
et al17 showed little expression of the transgene and only small
changes in plasma lipoproteins. Jiang et al18 reported a 29%
increase in PLTP activity, but significant effects on total plasma
lipids or lipoproteins were not observed. After their HuPLTP
transgenic mice were crossbred with mice transgenic for human
apoA-I, they detected minimal effects on plasma lipids and
lipoproteins (including an increase in pre-b-HDL levels), to-
gether with a 47% elevation in plasma PLTP activity. It must be
noted that compared with wild-type mice, human apoA-I trans-
genic mice already have elevated levels of total and pre-b-HDL
cholesterol.18 The HuPLTP transgenic mice described in the
present study have altered HDL metabolism, without the com-
plication of the additional human apoA-I gene, which by itself
has substantial effects on HDL. Moreover, our mice are not
transgenic for lysosomal protective protein. Jiang et al18 used a
DNA construct containing both genes that have a 39 overlap on
opposite DNA strands. Although unlikely, it is difficult to
exclude the possibility that this condition interferes with lipopro-
tein metabolism.
HuPLTP has also been overexpressed in mice via adenovirus-
mediated transfer.31,32 These mice showed a 13- to 40-fold
elevation of PLTP activity in plasma several days after treat-
ment. This resulted in a dramatic decrease (by 91%) in total
HDL cholesterol levels, whereas pre-b-HDL levels were sub-
stantially elevated.31 These data are in line with our present
observations: high PLTP activity results in a decrease in total
HDL, whereas pre-b-HDL levels are increased. It is clear that
the effects are transient and greatly exaggerated in the
adenovirus-treated mice, because of the extremely high plasma
levels of PLTP. Four-fold–elevated PLTP activity levels, mea-
sured at late time points after adenovirus transfection, did not
result in altered plasma HDL cholesterol concentrations,
whereas in our homozygous HuPLTP transgenic mice, a 4-fold
elevation in PLTP activity resulted in decreased HDL concen-
trations. Another notable difference is that in the adenovirus-
treated mice, PLTP expression is restricted to the liver. The
tissue pattern of expression of the HuPLTP gene in transgenic
mice more closely resembles the pattern of expression of the
endogenous PLTP gene (Figure 3).33
Compared with plasma of wild-type mice, the plasma of
HuPLTP transgenic mice was found to be much more efficient
in partially preventing the AcLDL-induced accumulation of
intracellular cholesterol in cultured macrophages, in spite of
lower levels of total HDL.
The most likely explanation for this observation is the
increased plasma concentration of pre-b-HDL, which has been
identified previously as a very efficient cholesterol acceptor.13,14
It is well known that an operative cholesteryl ester cycle, as
present in macrophages,34,35 is important for cholesterol efflux.
Miyazaki et al36 show that dimyristoylphosphatidylcholine/
apoA-I complexes, but not HDL, may modify AcLDL in a
concentration-dependent manner, resulting in decreased cellular
uptake. However, the plasma concentration of pre-b-HDL is not
increased in our HuPLTP transgenic mice. Therefore, it is
unlikely that the prevention of cellular cholesterol accumulation
by transgenic mouse plasma is due to decreased uptake of
AcLDL by the macrophages. The present results imply that the
distribution of HDL subclasses is of major importance in the
efficacy of HDL-mediated reverse cholesterol transport; it is
even more important than total plasma HDL levels. Compared
with plasma from hemizygous mice, plasma from homozygous
HuPLTP transgenic animals appeared to be more efficient in
preventing cellular cholesterol accumulation, indicating a dose
response for the effect of PLTP on cellular cholesterol. In
addition to the proposed mechanism of action of PLTP on
cellular cholesterol efflux via the generation of pre-b-HDL,
PLTP could also contribute directly to cellular cholesterol efflux
via its proposed cholesterol transfer activity.37
Plasma levels of total HDL cholesterol are inversely corre-
lated with the incidence of coronary artery disease in humans.7,8
However, only a few studies have looked at the relation between
total HDL and pre-b-HDL in human plasma. Recently,
O’Connor et al14 analyzed the steady-state levels of pre-b-HDL
in 136 normolipidemic individuals by using an isotope-dilution
technique. Their relative values for pre-b-HDL in human plasma
are quite comparable to the values measured in mouse plasma
(see Table 2). The percentage of pre-b-HDL (percentage of total
plasma apoA-I) was negatively correlated with total HDL
cholesterol concentrations, in line with our observations in mice.
Plasma PLTP activity was not measured in their study.
Reconstituted HDL particles enriched in triglycerides, which
are model particles for HDL prevalent during alimentary li-
pemia, are more rapidly converted by PLTP to pre-b-HDL than
are triglyceride-poor HDL particles.38 This observation suggests
that hypertriglyceridemia may be associated with increased
generation of pre-b-HDL by PLTP. In addition, Syva¨nne et al39
reported a positive correlation between PLTP activity and the
capability of plasma from patients with diabetes mellitus and
coronary heart disease to induce cholesterol efflux from Fu5AH
rat hepatoma cells.
Taken together, the combination of increased PLTP activity,
increased pre-b-HDL formation, and less accumulation of cel-
lular cholesterol (as seen in our mouse model) is likely to exist
also in the human situation. The rate of formation of pre-b-HDL
may very well be more important than its steady-state concen-
tration. The present work shows for the first time that PLTP is
important in the ongoing generation of plasma pre-b-HDL and
that the ability of plasma to prevent cholesterol accumulation in
macrophages is increased at high PLTP activity levels. Our
findings show that PLTP is a potential antiatherogenic factor
because of its ability to generate pre-b-HDL. To test this
hypothesis directly in vivo, we will perform a comparative study
in which the susceptibility to diet-induced atherosclerosis will be
evaluated. We are currently expanding the colony of HuPLTP
transgenic mice to this end. Because the PLTP-expressing mice
are expected to be even more resistant to diet-induced athero-
sclerosis than are wild-type mice, these experiments will be very
time-consuming. Another approach will be to measure (diet-
induced) atherogenesis in mouse models susceptible to the
development of atherosclerosis (eg, that due to LDL receptor
deficiency40 or apoE deficiency41,42), with and without overex-
pression of HuPLTP.
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